To investigate the efficacy and safety of bevacizumab in cervical cancer with lung metastasis (CCLM) .

Patients of CCLM admitted to Qingdao Central Hospital between 2015 and 2018 were retrospectively analyzed. Multivariate analysis of the Cox model affected the prognostic factors in patients with lung metastasis of cervical cancer. Stratified analysis of the difference in outcomes using the bevacizumab group versus no bevacization group.

A total of 31 patients with CCLM were included in this study. Only pulmonary metastasis occurred in 7 cases (23%) and multiple site metastasis occurred in 24 cases (77%) . After recurrence, 9 patients received local treatment including surgery and radiotherapy, and 22 patients only received chemotherapy. 15 patients (48%) received bevacizumab, 16 patients (52%) did not receive bevacizumab. The mean progression free survival (PFS) was 20.5 months, and the mean survival after recurrence (SAR) was 20.0 months. The mean overall survival (OS) was 40.5 months. Cox multivariate analysis showed that stage (HR=6.247, 95% CI: 1.294-30.156, P=0.023) , without surgery or radiotherapy after recurrence (HR=5.903, 95%CI: 1.211-28.780, P=0.028) , without bevacizumab treatment after recurrence (HR=21.475, 95%CI: 3.637-126.818, P=0.001) were independent risk factors for prognosis. Stratified analysis showed that in patients without surgery or radiotherapy after recurrence, the SAR and OS of who receiving bevacizumab were significantly higher than those receiving bevacizumab ( (27±2) months vs (17±3) months, P= 0.044 and (74±6) months vs (26±3) months, P=0.001) . The OS of patients with stage ⅡB or more receiving bevacizumab was significantly higher than that of patients without bevacizumab (P=0.020) .

Chemotherapy combined with bevacizumab can improve the prognosis of patients of cervical cancer with lung metastasis and multiple metastasis.

Cervical cancer; Lung metastasis; Bevacizumab; Prognosis